ライフサイエンスコーパス: epoxygenase

1 pase C (PLC) or cytochrome P450 arachidonate epoxygenase.

2 ed by PPOH and miconazole, inhibitors of CYP/epoxygenase.

3 tosolic phospholipase A2 and cytochrome P450 epoxygenase.

4 ls expressing high levels of cytochrome P450 epoxygenase.

5 - and enantioselective arachidonic acid (AA) epoxygenase.

6 mical selectivity of the kidney arachidonate epoxygenase.

7 bic oxygen/substrate binding site within the epoxygenase.

8 ) excretion, expresses cytochrome P450 (CYP)-epoxygenase.

9 oteinase-activated receptor-2 and cytochrome epoxygenase.

10 rome P450 as the endogenous arachidonic acid epoxygenase.

11 nvolves phospholipase A2 and cytochrome P450 epoxygenases.

12 small molecules produced by cytochrome P450 epoxygenases.

13 ted from arachidonic acid by cytochrome P450 epoxygenases.

14 athways of lipoxygenase, cyclooxygenase, and epoxygenase, 12-lipoxygenase of the lipoxygenase pathway

15 regio- and stereoselective arachidonic acid epoxygenase ((14S,15R)-epoxyeicosatrienoic acid, 99% of

16 he renal expression of cytochrome P450 (CYP) epoxygenase 2C23, which metabolizes arachidonic acid (AA

17 Endothelial cells lacking a Cyp2c44 epoxygenase, a PPARalpha target, show reduced proliferat

18 Finally, inhibition of CYP-epoxygenase abolished iberiotoxin-sensitive and flow-sti

19 -modifying enzymes (desaturase, hydroxylase, epoxygenase, acetylenase, and conjugase) revealed severa

20 ired or inherited abnormalities in the renal epoxygenase activities and/or regulation and salt-sensit

21 f AA and 11,12-EET on ENaC by increasing CYP epoxygenase activity and decreasing sEH activity, respec

22 Epoxygenase activity decreased by 28%, 51%, and 26% in F

23 an essential role for Stat3 as a mediator of epoxygenase activity in breast cancer.

24 mal arachidonic acid metabolism, (2) reduced epoxygenase activity in F48 and F48/R6 rats is accompani

25 bronectin expression is under the control of epoxygenase activity in human and rat primary macrophage

26 Inhibition of epoxygenase activity inhibited progesterone production s

27 CYP epoxygenase activity was analyzed by reverse-phase high-

28 m chloride (NaCl) for 7 days increased renal epoxygenase activity, both in the cortex and the medulla

29 nked to PLC and cytochrome P450 arachidonate epoxygenase activity.

30 fflux of 20-HETE, whereas 2% NaCl stimulated epoxygenase activity.

31 t this treatment had only a modest effect on epoxygenase activity.

32 sion of [(14)C]AA to HETEs without affecting epoxygenase activity.

33 ogical inhibition of brain P450 arachidonate epoxygenases also blocked morphine antinociception in mi

34 The enzyme consists of a terminal oxygenase (epoxygenase), an NADH-dependent reductase (reductase) an

35 antihypertensive role for the kidney Cyp2c44 epoxygenase and for its epoxyeicosatrienoic acid (EET) m

36 uces the activity of the kidney arachidonate epoxygenase and markedly increases the urinary excretion

37 0 2C23 matched that of the kidney microsomal epoxygenase and that excess dietary salt does not alter

38 pression and activity of the cytochrome P450 epoxygenases and hydroxylases.

39 al expression of the human CYP2J2 and CYP2C8 epoxygenases and mice with targeted disruption of Ephx2.

40 tial to mimic the activities of typical P450 epoxygenases and some capabilities of P450 hydroxylases.

41 P2J3 are abundant pulmonary arachidonic acid epoxygenases and that CYP2J products, the epoxyeicosatri

42 ocusing particularly on the CYP450 family of epoxygenases and the lipid mediators they produce.

43 evaluate in a systematic way the role of CYP epoxygenases and the metabolites they generate in cancer

44 etermined by the activity of cytochrome P450 epoxygenases and the soluble epoxide hydrolase (sEH), an

45 tabolites of cyclooxygenases, lipoxygenases, epoxygenases, and other sources.

46 idomic study revealed a dramatic increase in epoxygenase- and lipoxygenase-pathway-derived lipid medi

47 Here we show that the cytochrome P450 epoxygenase arachidonic acid metabolite 14,15-epoxyeicos

48 CYP epoxygenases are directly inhibited by H2O2, and this in

49 ), the catalytic products of cytochrome P450 epoxygenases, are PPARgamma ligands.

50 athways involving astrocytic cytochrome P450 epoxygenase, astrocytic cyclooxygenase-1 and smooth musc

51 rs of phospholipase A(2) and cytochrome P450 epoxygenase attenuated the sustained response, suggestin

52 Epoxygenases belong to the cytochrome P450 family.

53 nd rat intestine contain an arachidonic acid epoxygenase belonging to the CYP2J subfamily that is loc

54 Inhibition of the epoxygenase blocked serum-induced endothelial cell proli

55 Inhibiting CYP-epoxygenase but not cyclooxygenase- or CYP-omega-hydroxy

56 ufficient, catalytically active arachidonate epoxygenase can be constructed by fusing P450 2C11 to ma

57 We show here that lack of a Cyp2c44 epoxygenase causes dietary salt-sensitive hypertension,

58 The epoxygenase component contains a bridged diiron centre s

59 The epoxygenase component of this system has been purified w

60 These results indicate that the epoxygenase contains a bridged dinuclear iron centre sim

61 Cytochrome P450 epoxygenases convert arachidonic acid into 4 epoxyeicosa

62 luded lipoxygenase (LO)- and cytochrome P450 epoxygenase (CYP)-derived eicosanoids.

63 The cytochrome P450 epoxygenase (CYP)-derived metabolites of arachidonic aci

64 EET) by the cytochrome P450 arachidonic acid epoxygenases (Cyp2c) represents a new and safe mechanism

65 Cytochrome P450 (CYP) epoxygenases CYP2C8 and CYP2J2 generate epoxyeicosatrien

66 a new human cytochrome P450 arachidonic acid epoxygenase (CYP2J2) and the corresponding rat homologue

67 described a new human P450 arachidonic acid epoxygenase (CYP2J2) and the corresponding rat homologue

68 12-EET, or overexpression of the endothelial epoxygenase, CYP2J2, increased tissue plasminogen activa

69 ed gene deletion of the major rat macrophage epoxygenase Cyp2j4 (ortholog of human CYP2J2) resulted i

70 ken together, these results identify the rat epoxygenase Cyp2j4 as a determinant of a profibrotic mac

71 increased expression of the cytochrome-P450-epoxygenase CYP2J6 and increased concentrations of its l

72 phospholipase A2 (PLA2) and cytochrome P450 epoxygenases (CYP450s) were able to block the laminar fl

73 YP2J2 in the rat, as well as the role of CYP-epoxygenase-dependent metabolism of arachidonic acid in

74 Thus, these cP450 epoxygenase-dependent metabolites are a novel class of e

75 esent study describes a novel group of cP450 epoxygenase-dependent metabolites of arachidonic acid, t

76 ibition of ENaC, an effect mediated by a CYP-epoxygenase-dependent pathway.

77 Cyclooxygenase, lipoxygenase, and epoxygenase derived oxylipins, especially eicosanoids, p

78 cyclooxygenase- or cytochrome P450-dependent epoxygenase-derived AA metabolites, are specifically req

79 xygenase inhibitor, directly implicating CYP epoxygenase-derived EETs with the observed anti-inflamma

80 gh the cAMP-PKA pathway and suggest that CYP epoxygenase-derived eicosanoids may play important roles

81 osatrienoic acids (EETs) are cytochrome P450-epoxygenase-derived metabolites of arachidonic acid that

82 pathways; (b) provide evidence for a Cyp2c44 epoxygenase, EET-mediated mechanism of ENaC regulation i

83 Moreover, transfection of a bacterial 14,15-epoxygenase established intracellular endogenous 14,15-E

84 is a keratinocyte-specific arachidonic acid epoxygenase expressed in the granular cell layer of mous

85 alpha down-regulates endothelial cell CYP2C9 epoxygenase expression and blunts proliferation and tubu

86 a demonstrate that increased endothelial CYP epoxygenase expression attenuates afferent arteriolar co

87 (EETs), hepatic EET biosynthesis, and Cyp2c epoxygenase expression.

88 an active regio- and stereoselective 14S,15R-epoxygenase (F87V BM-3).

89 cells) expressing a mutant bacterial P450 AA epoxygenase, F87V BM3, which was genetically engineered

90 al infusion of inhibitors of cytochrome P450 epoxygenases (fluconazole) and NO synthase (N(G)-monomet

91 g results showed that protein expressions of epoxygenases from cytochrome P450 (CYP)2B, 2C and 2J sub

92 lipid mediators produced by cytochrome P450 epoxygenases from omega-3 fatty acid docosahexaenoic aci

93 We conclude that endothelial CYP epoxygenase function contributes to the regulation of bl

94 e of the PPARalpha receptor and of its Cyp2c epoxygenase gene target in tumorigenesis, we treated mic

95 , characterize the contribution of its Cyp2c epoxygenases gene target to these responses, and suggest

96 Cytochrome P450 (CYP) epoxygenases generate bioactive lipid epoxides which can

97 mega-hydroxylases and Cyp2c arachidonic acid epoxygenase genes.

98 om arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiova

99 acid omega-hydroxylase and arachidonic acid epoxygenase in the noninfected cells, (b) the CYP 4A3-de

100 P-450 2C23 is the major 2C arachidonic acid epoxygenase in the rat kidney and the renal P-450 isofor

101 ET) was the major product metabolized by CYP epoxygenases in rat corpora cavernosa.

102 s support a physiological role for 14,15-EET epoxygenases in regulating epidermal cornification, and

103 ference in the levels of the CYP2E and CYP2C epoxygenases in SHR and WKY kidneys.

104 ans, we establish the relative expression of epoxygenases in these cells.

105 ienoic acids, vasodilator metabolites of CYP/epoxygenase, in arterioles incubated with 17beta-E2, a r

106 r results suggest that EETs, produced by CYP epoxygenases, in penile endothelial cells serve as vasod

107 s, products of the kidney P-450 arachidonate epoxygenase, inhibit distal nephron Na(+) reabsorption.

108 y added EETs rescued cell proliferation from epoxygenase inhibition.

109 hannel activity, even in the presence of CYP-epoxygenase inhibition.

110 d both were reduced to similar levels by CYP epoxygenase inhibition.

111 ith cirrhosis were treated with the specific epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynylox

112 ic features that were ameliorated by the CYP epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynylox

113 Perfusion with the selective P450 epoxygenase inhibitor N-methylsulphonyl-6-(2-proparglylo

114 The epoxygenase inhibitor SKF525A (epoxI) given at 24 h sele

115 e dilation was unaffected by cytochrome-P450 epoxygenase inhibitor sulfaphenazole.

116 ooxygenase inhibitor) and sulfaphenazole (an epoxygenase inhibitor).

117 y a putative EET receptor antagonist and CYP epoxygenase inhibitor, directly implicating CYP epoxygen

118 A), the 5-lipoxygenase inhibitor, AA861, the epoxygenase inhibitor, miconazole, and the cyclooxygenas

119 Both epoxygenase inhibitors completely prevented the arachido

120 oxygenase, lipoxygenase, or cytochrome P-450 epoxygenase inhibitors did not reverse the inhibition ca

121 In contrast, the cytochrome P-450 epoxygenase inhibitors, SKF525A and metyrapone, substant

122 cts were inhibited by preincubation with CYP epoxygenase inhibitors.

123 xygenases, but not cytochrome P450-dependent epoxygenases inhibits Ang II- or AA-induced RGS2 mRNA ex

124 angiogenesis and growth, and (c) the CYP2C9 epoxygenase is expressed in the vasculature of human tum

125 ETs or compared the effects of different CYP epoxygenase isoforms in the ischemic heart.

126 om arachidonate by inducible cytochrome P450 epoxygenase isoforms, and tissue EET profiles may vary w

127 y human recombinant CYP 2C9 and 2J2, 2 major epoxygenase isozymes expressed in human coronary arterio

128 CYP2C44 epoxygenase knockdown blunted the sodium transport effec

129 as ENaC inhibitors, and (d) suggest a CYP2C epoxygenase-mediated pathway for the regulation of dista

130 Our findings indicate that a neuronal P450 epoxygenase mediates the pain-relieving properties of mo

131 en endocannabinoid and cytochrome P450 (CYP) epoxygenase metabolic pathways.

132 study demonstrates that a P450 arachidonate epoxygenase metabolite can activate cleavage of heparin-

133 -epoxyeicosatrienoic acid, a cytochrome P450 epoxygenase metabolite of arachidonic acid, may be a com

134 eases in the plasma levels of pro-angiogenic epoxygenase metabolites (EETs), hepatic EET biosynthesis

135 The cytochrome P450 arachidonic acid epoxygenase metabolites are resolved, without the need f

136 ze a mechanistic commonality between EGF and epoxygenase metabolites as ENaC inhibitors, and (d) sugg

137 ated biological activities attributed to the epoxygenase metabolites in cell proliferation, angiogene

138 noic acids (EETs), the cytochrome P450 (CYP) epoxygenase metabolites of arachidonic acid (AA), are po

139 Epoxygenase metabolites of arachidonic acid are produced

140 satrienoic acids (EETs), the cytochrome P450 epoxygenase metabolites of arachidonic acid, are potent

141 Roles for the arachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (

142 The cytochrome P450 arachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (

143 harmacological inhibition of cytochrome P450 epoxygenases opened the myocardial mPTP in human heart m

144 denovirus particles expressing a 14S,15R-EET epoxygenase (P450 BM3v).

145 t unequivocal evidence for a role for the AA epoxygenase pathway and endogenous EET synthesis in EGF-

146 ata demonstrate that potentiation of the CYP epoxygenase pathway by either increased endothelial EET

147 s of ion channels, little is known about the epoxygenase pathway in labor.

148 Epoxygenase pathway metabolites are established regulato

149 Ts are produced by the cytochrome P450 (CYP) epoxygenase pathway of arachidonic acid (AA) metabolism

150 Blockade of the epoxygenase pathway was ineffective, whereas blocking ei

151 ion, high dietary K stimulates the renal CYP-epoxygenase pathway, which plays an important role in ac

152 ing the central roles of the cytochrome P450 epoxygenase pathway.

153 rough cyclooxygenase, lipoxygenase, or P-450 epoxygenase pathways can generate a variety of eicosanoi

154 es for the cyclo-oxygenase, lipoxygenase and epoxygenase pathways, but specific inhibitors of these p

155 which are products of cytochrome P450 (CYP) epoxygenases, possess vasodilatory, antiinflammatory, an

156 cosatetraenoic; however, the cytochrome P450 epoxygenase product 5,6-epoxyeicosatrienoic acid is prim

157 onic acid (AA) metabolism and synthesized AA epoxygenase products (+/-)-8,9-, (+/-)-11,12-, and (+/-)

158 cells represents not only a novel action of epoxygenase products from EFAs, but also a potentially s

159 The epoxygenase products, the epoxyeicosatrienoic acids, are

160 Furthermore, cytochrome P450 epoxygenase promotes cell survival both by production of

161 lipid mediators produced by cytochrome P450 epoxygenases, regulate inflammation, angiogenesis, and v

162 ha points to a role for the receptor and its epoxygenase regulatory target in the pathophysiology of

163 olism of arachidonic acid by the mouse renal epoxygenase(s).

164 ut not of cyclooxygenase or cytochrome P-450 epoxygenase, significantly attenuated the vasodilations

165 s into the proposed active-site model of the epoxygenase suggested that Ala91 and Ala185 were respons

166 cids (EETs) are products of cytochrome P-450 epoxygenase that possess important vasodilating and anti

167 s indicate that CYP3A4 is a highly active AA epoxygenase that promotes Stat3-mediated breast cancer c

168 (EETs) are products of cytochrome P450 (CYP) epoxygenases that have vasodilatory and anti-inflammator

169 acids (EETs) are products of cytochrome P450 epoxygenases that have vasodilatory properties similar t

170 ere blocked by inhibitors of cytochrome P450 epoxygenase, the synthetic enzyme for epoxyeicosatrienoi

171 arachidonate is oxidized by cytochrome P-450 epoxygenases to four epoxyeicosatrienoic acids (EETs): 1

172 al expression of the human CYP2J2 and CYP2C8 epoxygenases to increase endothelial EET biosynthesis.

173 ne line of mice harboring a cardiac-specific epoxygenase transgene developed head swelling and rapid

174 ing a human cytochrome P450 arachidonic acid epoxygenase was isolated from a human liver cDNA library

175 Brain cytochrome P450 epoxygenases were recently shown to play an essential ro